Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02001623 (Clinical trial / Tisotumab vedotin / HuMax®-TF-ADC / TF-011-MMAE)

Study Title
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors (NCT02001623)

Trial Description
The purpose of the trial is to establish the tolerability of HuMax®-TF-ADC (TF-011-MMAE)in a mixed population of patients with specified solid tumors.

This trial is sponsored by Genmab. [1]

Study Data

  • Conditions: Ovary, Cervix, Endometrium, Bladder, Prostate, Esophagus, and Lung Cancer
  • Interventions:
    • Drugs used in this trial
      • HuMax®-TF-ADC (TF-011-MMAE)
  • Phase: I
  • Estimated Enrollment: 144
  • Start: November 2013
  • Estimated Completion: February 2018
  • Last verified: April 2017

Study Schematic 


Last Editorial review: September 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar